Both in Pharmaceuticals
Lyell Immunopharma vs Rezolute, Inc. Common Stock (NV)
Over the past year LYEL returned −3.3% and RZLT returned −55.5%; their daily moves had a correlation of 0.01.
LYEL −3.3% RZLT −55.5%Growth of $1, one year, split-adjusted
| Metric | LYEL | RZLT |
|---|---|---|
| Price | $15.43 | $3.96 |
| Market cap | $378.1M | $383.0M |
| Today | +43.27% | −1.25% |
| 1 month | +79.2% | −8.3% |
| 6 months | −26.0% | +26.1% |
| Year to date | −49.9% | +67.8% |
| 1 year | −6.8% | −56.5% |
| Revenue growth (YoY) | −50.0% | — |
| Gross margin | 100.0% | — |
| Net margin | −1118875.0% | — |
| P/E (TTM) | — | — |
| Price / sales | 14,004.2× | — |
| Net cash | $204.1M | $107.8M |
| Dividend yield | — | — |
| Volatility (60d) | 101.1% | 60.1% |
| Short % of float | 15.8% | 22.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).